Ultragenyx Analysis: $3.3B Raised
What is Ultragenyx?
First-ever approved treatments for rare and ultrarare genetic diseases
Employees
1001-5000
Founded
2010
Valuation
$3.32 billion
HQ Full Address
Novato, California, United States
Revenue Growth Rate
19%
Product Features & Capabilities
- DTX401 for GSDIa
- DTX301 for OTC Deficiency
- UX701 for Wilson Disease
- UX143 for OI
- GTX-102 for AS
- UX111 for MPS IIIA
- UX055 for CDD
Investment Focus
Ultragenyx Pharmaceuticals primarily focuses on developing therapies for rare and ultrarare genetic diseases. Their therapeutic areas include metabolic genetic diseases, neurological genetic disorders, and rare pediatric conditions. Specific conditions they are targeting include Glycogen Storage Disease Type Ia (GSDIa), Ornithine Transcarbamylase (OTC) Deficiency, Wilson Disease, Osteogenesis Imperfecta (OI), Angelman Syndrome (AS), Mucopolysaccharidosis Type IIIA (MPS IIIA), and Congenital Disorders of Glycosylation (CDD).
Other Considerations
Serves patients with debilitating genetic conditions where no prior treatments exist; One of the most robust and diverse clinical pipelines in rare disease; Focus on patient-centered development and commercialization; Founded in 2010; Employee count: 1001-5000; HQ in Novato, US; Operations in 13 countries including Japan, Germany, France, Brazil, Mexico, Canada, Spain, UK, Italy, Chile, Colombia, Peru; Active in patient advocacy through UltrarareAdvocacy.com; Appoints new executives regularly; Reports inducement grants under Nasdaq rules
Latest Funding Round
Ultragenyx Pharmaceuticals is looking to raise approximately $350 million in a public stock offering, which was announced on June 14, 2024. The offering was priced at around $39 per share.
Awards Recognition
Ultragenyx Pharmaceuticals has received several awards and recognitions in the biotech field, including:
1. Emil Kakkis, M.D., Ph.D., the CEO of Ultragenyx, received the 2021 Pantheon Leadership Award from California Life Sciences, which also recognized Ultragenyx as a finalist for Company of the Year.
2. Emil D. Kakkis was awarded BIO's 2019 Henri A. Termeer Biotechnology Visionary Award.
3. Ultragenyx was recognized as the Most Dedicated Rare Disease Medicine Development Biopharma Company in North America at the 2023 CSR Awards.
4. In 2022, Global Health & Pharma named Ultragenyx the Best Leading Rare Disease Medicines & Therapies Company in their Healthcare and Pharmaceutical Awards.
5. Recently, Ultragenyx earned an award for Outstanding Contributions to the Massachusetts Economy.
1. Emil Kakkis, M.D., Ph.D., the CEO of Ultragenyx, received the 2021 Pantheon Leadership Award from California Life Sciences, which also recognized Ultragenyx as a finalist for Company of the Year.
2. Emil D. Kakkis was awarded BIO's 2019 Henri A. Termeer Biotechnology Visionary Award.
3. Ultragenyx was recognized as the Most Dedicated Rare Disease Medicine Development Biopharma Company in North America at the 2023 CSR Awards.
4. In 2022, Global Health & Pharma named Ultragenyx the Best Leading Rare Disease Medicines & Therapies Company in their Healthcare and Pharmaceutical Awards.
5. Recently, Ultragenyx earned an award for Outstanding Contributions to the Massachusetts Economy.
Partnerships
- Solid Biosciences - A strategic collaboration to develop and commercialize new gene therapies for Duchenne muscular dystrophy, announced on October 23, 2020.
- Mereo BioPharma - A collaboration and license agreement for Setrusumab in Osteogenesis Imperfecta, announced on December 17, 2020.
- Regeneron Pharmaceuticals - A collaboration to clinically develop, commercialize, and distribute Evkeeza® (evinacumab), announced on January 7, 2022.
- GeneTx Biotherapeutics - A partnership to develop GeneTx's GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome, announced on August 14, 2019.
- Arcturus Therapeutics - An expanded collaboration to develop mRNA therapies, announced on June 19, 2019.
Key Innovations
- Burosumab (Crysvita) - Approved for the treatment of X-linked hypophosphatemia (XLH).
- Triheptanoin (UX007) - Approved for the treatment of long-chain fatty acid oxidation disorders.
- Vestronidase alfa (Mepsevii) - Approved for the treatment of mucopolysaccharidosis VII (MPS VII).
- Pipeline Products - - **DTX301** for Ornithine Transcarbamylase (OTC) deficiency. - **DTX401** for Glycogen Storage Disease Type Ia (GSDIa). - **UX111** for Mucopolysaccharidosis IIIA (MPS IIIA). - **UX143** for Osteogenesis Imperfecta (OI).
Regulatory Approvals
- Burosumab (Crysvita) - Approved by the FDA for the treatment of X-linked hypophosphatemia (XLH).
- Triheptanoin (Dojolvi) - Approved by the FDA for the treatment of long-chain fatty acid oxidation disorders.
- Vestronidase alfa (Mepsevii) - Approved by the FDA for the treatment of mucopolysaccharidosis VII (MPS VII).
- Evkeeza (evinacumab) - Recently received approval from the European Commission for use in children aged six months to less than five years with homozygous familial hypercholesterolemia (HoFH).
- UX111 - A Biologics License Application (BLA) has been submitted to the FDA for this AAV gene therapy targeting Sanfilippo Syndrome Type A, which is currently under priority review.
